Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Synature Ltd

15 Nov 2005 07:03

Angle PLC15 November 2005 For immediate release 15 November 2005 ANGLE plc ("ANGLE") SENIOR APPOINTMENTS AND VENTURE UPDATE ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce two senior appointments at its venture company, SynatureLtd. Founded earlier this year, Synature Ltd (formerly known as Customiser Group Ltd)provides psychological profiling tools that engage the consumer, deliveringinsight into individual attitudes and consumer preferences complementingtraditional demographic models. Based in Guildford Surrey, Synature Ltd is oneof ANGLE's eight venture companies. Dr. John Woods joins Synature Ltd as Chief Executive Officer. Previously founderand Chief Executive of Site Intelligence Ltd, one of the UK's most successfulweb analytics companies, John has worked with clients such as Argos, Expedia,SAP and Lloyds TSB. Dr. Woods has 15 years' experience in commercialisation and marketing ofadvanced software technologies. He holds a doctorate from Jesus College, Oxfordand an MBA. Commenting on his appointment, Dr. Woods said "I am delighted to be joining the Synature team at this exciting stage in thecompany's development. Marketing departments have a growing appetite forenhanced profiling and targeting of online and offline customers. Synature'sunique intellectual property offers a compelling way to meet that need.Moreover, ANGLE provides Synature with a supportive environment in which thatcompelling intellectual property can be rapidly and successfully commercialised." Professor William J. Fitzgerald joins Synature Ltd as a consultant technicaladvisor. He is Professor of Applied Statistics and Signal Processing and Headof the Signal Processing and Communications Laboratory at the University ofCambridge. He consults for a number of successful high technology companies inboth the UK and USA. Professor Fitzgerald commented: "Synature's consumer profiling techniques demonstrate the real world businessbenefits that can be obtained from state-of-the-art data analysis and patternrecognition. I am excited to be part of the team and to be ensuring thatSynature's clients receive maximum insight and maximum value from theapplication of our technologies." Stephen Bence, Director of New Ventures at ANGLE, added: "These two key appointments complement Synature's existing founding team andprovide the company with additional commercial and technical expertise. We areexcited about the opportunity that Synature's unique intellectual propertyrepresents." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Synature Ltd 08701 909550John Woods, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com Synature Ltd is an ANGLE Technology group company formed to commercialiseintellectual property acquired in 2005 from Customiser Ltd. Synature'sintellectual property provides unique ways to profile consumers in terms oftheir underlying preferences. The resulting profiles allow fine-grainedconsumer segmentation that complements traditional demographics. Synature'stechniques can be applied both online and offline. Further information can be found on www.synature.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.